Literature DB >> 17944029

Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.

Kenneth Martin1, Delphine Borgel, Nicolas Lerolle, Hendrik B Feys, Ludovic Trinquart, Karen Vanhoorelbeke, Hans Deckmyn, Paulette Legendre, Jean-Luc Diehl, Dominique Baruch.   

Abstract

OBJECTIVE: The inability to regulate the inflammatory response initiated upon infection leads to severe sepsis, characterized by widespread microvascular injury and thrombosis, organ ischemia, and dysfunction. A disintegrin-like and metalloprotease with thrombospondin type 1 repeats (ADAMTS)-13 regulates primary hemostasis by proteolyzing von Willebrand factor (VWF). Decreased ADAMTS-13 has been reported in disseminated intravascular coagulation due to severe sepsis. The present study investigates whether the sepsis-related dysregulation of endothelial activation leads to specific changes of ADAMTS-13.
DESIGN: Case-control study.
SETTING: Adult intensive care unit in a university hospital. PATIENTS/
SUBJECTS: Three groups were studied: a case group of 30 patients with severe sepsis, a control group of 29 patients with comparable organ failure unrelated to sepsis, and 30 age- and gender-matched healthy subjects.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Significantly lower ADAMTS-13 activity was observed in patients with severe sepsis (43.2%; interquartile range, 32.7, 67.0) than in patients with organ failure unrelated to sepsis (67.8%; 57.4, 87.9; p < .05) and healthy subjects (105.6%; 87.2, 125.6; p < .001). Accordingly, ADAMTS-13 antigen was more decreased in patients with severe sepsis than in patients with organ failure unrelated to sepsis and healthy subjects. VWF antigen was higher in patients with severe sepsis than in patients with organ failure unrelated to sepsis and healthy subjects. We found strong negative correlations in severe sepsis but not in organ failure unrelated to sepsis, between ADAMTS-13 activity and 1) VWF antigen; 2) thrombomodulin; 3) interleukin-6; 4) Acute Physiology and Chronic Health Evaluation II score; 5) shock; 6) acute renal injury. Moreover, patients above the median of ADAMTS-13 activity presented a higher survival compared with those below the median in the patients with severe sepsis but not in the patients with organ failure unrelated to sepsis. In contrast, there was no significant association between VWF antigen and survival in either the severe sepsis group or the group with organ failure unrelated to sepsis.
CONCLUSIONS: We observed low ADAMTS-13 activity and antigen in severe sepsis and in other conditions associated with organ dysfunction. ADAMTS-13 levels were significantly associated with differences in morbidity, mortality, and variables of inflammation and endothelial dysregulation only in severe sepsis patients. This suggests that ADAMTS-13 deficiency may have a pathophysiological relevance specific to severe sepsis. (C) 2007 Lippincott Williams & Wilkins, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944029     DOI: 10.1097/01.ccm.0000284508.05247.b3

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  42 in total

Review 1.  ADAMTS proteins in human disorders.

Authors:  Timothy J Mead; Suneel S Apte
Journal:  Matrix Biol       Date:  2018-06-06       Impact factor: 11.583

Review 2.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

3.  ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis.

Authors:  Astrid Alflen; Steve Prüfer; Katharina Ebner; Sebastian Reuter; Pamela Aranda Lopez; Inge Scharrer; Fumiaki Banno; Michael Stassen; Hansjörg Schild; Kerstin Jurk; Markus Bosmann; Hendrik Beckert; Markus P Radsak
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

4.  IL-1β down-regulates ADAMTS-13 mRNA expression in cells of the central nervous system.

Authors:  G Alkistis Frentzou; Claire Bradford; Kirsty A Harkness; Gail Haddock; M Nicola Woodroofe; Alison K Cross
Journal:  J Mol Neurosci       Date:  2011-07-06       Impact factor: 3.444

5.  ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.

Authors:  Chintan Gandhi; Mohammad Moshahid Khan; Steven R Lentz; Anil K Chauhan
Journal:  Blood       Date:  2011-11-28       Impact factor: 22.113

6.  Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome.

Authors:  Sybille Pelras; Yahsou Delmas; Delphine Lamireau; Frédéric Villega; Paul Nolent; Anne Ryman; Brigitte Llanas; Olivier Brissaud; Jérôme Harambat
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

Review 7.  Could Biomarkers Direct Therapy for the Septic Patient?

Authors:  Clark R Sims; Trung C Nguyen; Philip R Mayeux
Journal:  J Pharmacol Exp Ther       Date:  2016-02-08       Impact factor: 4.030

8.  Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.

Authors:  Juan Xiao; Sheng-Yu Jin; Jing Xue; Nicoletta Sorvillo; Jan Voorberg; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-28       Impact factor: 8.311

Review 9.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

10.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.

Authors:  Junmei Chen; Xiaoyun Fu; Yi Wang; Minhua Ling; Brad McMullen; John Kulman; Dominic W Chung; José A López
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.